Asia On The Move: China Startups Go On Hiring Spree
This article was originally published in PharmAsia News
As investment pours into Chinese biologic startups, a talent hunt is on, underscored by two announcements of new senior appointments at CANbridge and Zai Lab. Meanwhile, clinical research organization ICON has appointed new leadership for Asia and Meiji Seika is strengthening its CNS business.
You may also be interested in...
With the fourth quarter just around the corner, China's closely-watched annual drug reimbursement and prices negotiations are entering a key final stage. But will applicants need to be more strategic than expedient?
Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.
China’s Negative List for Foreign Investment explicitly bars “investment and application in human stem cells, genetic diagnosis, and treatment technologies.” But whether that applies to foreign pharma firms developing such modalities in the country remains unclear.